News | January 11, 2026
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Subscribe To Our Newsletter & Stay Updated
